Blog: Copper ATSM as a Potential Treatment for ALS | ALS Therapy Development Institute
First ALS Patient Enrolled in Phase 2/3 Trial of CuATSM
Blog: Copper Compound (CuATSM) Shows Promise in ALS Lab Studies | ALS Therapy Development Institute
CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background | Scientific Reports
Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model - ScienceDirect
Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy | PNAS
CuATSM is not tolerated at a high dose in a mice model of ALS - Padirac Innovations' blog
Blog: Phase 1 extension trial on CuATSM now enrolling in Australia | ALS Therapy Development Institute
CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease - Southon - 2020 - British Journal of Pharmacology - Wiley Online Library
An Update on Copper-ATSM and Clinical Trials for ALS, Updated March 2017 « Linus Pauling Institute Blog
PDF) CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background
PDF) CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits - ScienceDirect
Motor neurone disease breakthrough: Patient trial shows impressive clinical results
64Cu-ATSM Positron Emission Tomography/Magnetic Resonance Imaging of Hypoxia in Human Atherosclerosis | Circulation: Cardiovascular Imaging
Summary for ALS Patients about CuATSM and Clinical Trials « Linus Pauling Institute Blog
Blog: Copper ATSM Slows Down Disease in Independent Preclinical Testing at ALS TDI | ALS Therapy Development Institute
Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model - ScienceDirect
Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model - ScienceDirect
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits - ScienceDirect
Collaborative Medicinal Development Enrolls First Patient In a Randomized, Placebo-Controlled Clinical Trial of CuATSM For The Treatment of Amyotrophic Lateral Sclerosis
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy - International Journal of Radiation Oncology, Biology, Physics
New ALS drug slows disease progression in groundbreaking clinical trial
Structure of Cu-ATSM. | Download Scientific Diagram
CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease - Southon - 2020 - British Journal of Pharmacology - Wiley Online Library
